Sareum Holdings and SRI International develop drug for inflammatory diseases

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International.

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International.

The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials.

Research will focus on the development of small molecule the therapeutics targeting TYK2, one of the four janus kinase (JAK) family members implicated in a number of inflammatory diseases.

"The agreement with SRI gives us access to world-class autoimmune disease biology and drug development expertise," said Sareum's Chief Executive Officer Tim Mitchell.

"We are delighted to be working with SRI. As we have stated in the past, our intention has been to enter into agreements that help develop our research into commercially viable products in the most effective and efficient way."

SRI Biosciences' Center for Immunology and Infectious Diseases will co-lead discovery and development activities.

Annalisa D'Andrea, Senior Director of SRI's Center for Immunology and Infectious Diseases, added: "Because of TYK2's critical role in the signalling of inflammatory cytokines, there is strong scientific rationale for developing TYK2 inhibitors for the treatment of autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, sepsis, and Crohn's Disease."

Shares rose 7.32% to 1.10p at 08:19 Monday.

RD

Recommended

Four high-quality US stocks to give shelter from the storm
Share tips

Four high-quality US stocks to give shelter from the storm

Professional investor Timothy Parton of the JPMorgan American Investment Trust picks four solid US stocks to buy now.
24 May 2022
Three undervalued mid-cap stocks with attractive prospects
Share tips

Three undervalued mid-cap stocks with attractive prospects

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing mid-cap stocks to buy now.
24 May 2022
Britain’s ten most-hated shares – w/e 20 May
Stocks and shares

Britain’s ten most-hated shares – w/e 20 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
23 May 2022
Britain's most-bought shares w/e 20 May
Stocks and shares

Britain's most-bought shares w/e 20 May

A look at Britain's most-bought shares in the week ending 13 May, providing an insight into how investors are thinking and where opportunities may lie…
23 May 2022

Most Popular

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Everything is collapsing at once – here’s what to do about it
Investment strategy

Everything is collapsing at once – here’s what to do about it

Equity and bond markets are crashing, while inflation destroys the value of cash. Merryn Somerset Webb looks at where investors can turn to protect th…
23 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022